Form 4: Arrowhead Pharmaceuticals COO Sells Shares Following RSU Vesting

Arrowhead Pharmaceuticals' COO, Patrick O'Brien, sold a portion of his shares to cover tax obligations after restricted stock units vested, while also selling shares under a pre-arranged 10b5-1 trading plan.

Summary

• Patrick O'Brien, the COO and General Counsel of Arrowhead Pharmaceuticals, received 100,000 shares of common stock on January 4, 2025, as part of a restricted stock unit (RSU) grant that vests in four equal annual installments.
• On January 6, 2025, Mr. O'Brien sold 19,658 shares at a weighted average price of $19.69 and 9,526 shares at a weighted average price of $20.10.
• On January 7, 2025, he sold an additional 8,000 shares at a weighted average price of $19.69.
• These sales were partially to cover tax obligations related to the vesting of the RSUs and partially under a pre-arranged 10b5-1 trading plan.
• Following these transactions, Mr. O'Brien beneficially owns 527,201 shares of Arrowhead Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity related to stock-based compensation and a pre-arranged trading plan. There is no indication of positive or negative sentiment.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives who receive stock-based compensation. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The sale of shares by a company executive after RSU vesting is a common practice across the industry.
• The use of a 10b5-1 trading plan is a standard method for executives to sell shares without being accused of insider trading, and is widely used by executives at comparable companies such as Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS).
• The reported weighted average sale prices are within the typical range for stock transactions of this nature.

Stakeholder Impact

• The share sales by the COO may have a minor impact on the stock price, but are unlikely to significantly affect long-term investors.
• The transactions are part of standard executive compensation practices and should not negatively impact employee morale.

Key Dates

Keywords

insider trading, Form 4, stock sale, restricted stock units, 10b5-1 trading plan, executive compensation, share ownership, Arrowhead Pharmaceuticals, ARWR